

CLINICAL STRUCTURING & CRO STRATEGY FOR EARLY-STAGE BIOTECHS



Biotech Advisory Lab

FROM FUNDRAISING DECISIONS TO EXECUTION CONTROL.

Why Independent Advisory Matters

Early clinical strategy is not just a scientific question — it is a capital allocation decision.

Poor structuring at this stage leads to:

- Financial risk: capital raised does not match real execution needs
- Operational risk: CRO strategy built on incomplete assumptions
- Governance risk: execution control gradually shifts away from the sponsor

What Makes Biotech Advisory Lab Different

- Fully independent – zero vendor bias
- Built specifically for early-stage biotech constraints
- Dual perspective: clinical operations + financial structuring
- Governance-driven engagement model
- We operate at decision level — not task level

Our Advisory Model

LEVEL 1	LEVEL 2	LEVEL 3	LEVEL 4
Clinical Execution Readiness: Align clinical strategy with capital before entering the clinic.	Clinical Transition Structuring: Governance framework and operational alignment	Budget & CRO Proposals Evaluation: Independent benchmarking and financial validation	Ongoing CRO Oversight and Strategic Trial Governance: CRO governance and performance alignment

Typical Challenges We Address

- Limited clinical readiness at the point of fundraising
- Unclear CRO strategy and outsourcing approach
- Cash burn misaligned with execution reality
- Weak governance and decision-making structure

Key Stakeholders

- Early-stage biotech companies
- Investors & funding entities
- Venture creation & innovation ecosystem
- Strategic & operational partners

Start with an Independent CRO Readiness Assessment

Aurelio del Pino | Founder

apino@biotechadvisorylab.com

+34 611 771 660

www.biotechadvisorylab.com

